Eosinophil Proteins as Markers of Inflammation in Childhood Asthma
Abstract:Anti-inflammatory inhaled and oral corticosteroid treatment for airway inflammation in the asthmatic pediatric population requires prudent evaluation of clinical efficacy. Possible concomitant negative long-term side effects of potent corticosteroids administered in larger dosages are of particular concern in treatment of asthmatic children. A correlation between elevated serum levels of eosinophil cationic protein (ECP) released by activated eosinophils and the pathogenesis of asthmatic inflammation in children has recently been suggested. ECP may prove to be a clinically useful quantitative marker of the degree of lung inflammation as well as the efficacy of corticosteroid treatment in children who have asthma.
Document Type: Research Article
Publication date: 1994-05-01
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites